Prostate cancer Posts on Medivizor
Navigation Menu

Prostate cancer Posts on Medivizor

Evaluating the long-term functional and oncological outcomes after open versus robot-assisted prostate surgery for localized prostate cancer.

Evaluating the long-term functional and oncological outcomes after open versus robot-assisted prostate surgery for localized prostate cancer.

Posted by on Oct 24, 2021 in Prostate cancer | 0 comments

In a nutshell This study evaluated the long-term functional and oncological outcomes of robotic-assisted laparoscopic radical prostatectomy (RALP) and open retropubic radical prostatectomy (RRP) for the treatment of patients with localized prostate cancer (PCa). This study found that RALP was associated with better oncological outcomes compared to...

Read More

Reviewing focal therapies for patients with localized prostate cancer.

Reviewing focal therapies for patients with localized prostate cancer.

Posted by on Oct 16, 2021 in Prostate cancer | 0 comments

In a nutshell This article reviewed new studies on focal therapy (FT) in patients with localized prostate cancer (PCa), with a focus on treatment effectiveness.  Some background FT includes alternative, non-invasive methods for treating PCa. High-intensity focused ultrasound (HIFU) is a radiation-free technique that uses high-frequency ultrasound...

Read More

Is cancer treatment with immune checkpoint inhibitors associated with infection risk?

Is cancer treatment with immune checkpoint inhibitors associated with infection risk?

Posted by on Oct 9, 2021 in Prostate cancer | 0 comments

In a nutshell This study is aimed to evaluate the risk of infection for patients who are treated with immune checkpoint inhibitors (ICI) for solid tumors. The study concluded that in frail patients, ICI therapy alone is safer compared to chemotherapy (CT).   Some background Immunotherapy is a type of cancer treatment that makes use of the immune...

Read More

Apalutamide plus androgen deprivation therapy preserves health-related quality of life in patients with non-metastatic castration-resistant prostate cancer.

Apalutamide plus androgen deprivation therapy preserves health-related quality of life in patients with non-metastatic castration-resistant prostate cancer.

Posted by on Oct 9, 2021 in Prostate cancer | 0 comments

In a nutshell This study reported the long-term effects on the health-related quality of life (HR-QoL) of apalutamide (Erleada) in combination with androgen deprivation therapy (ADT) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC). The data showed that apalutamide plus ADT preserved HR-QoL in these patients. Some background...

Read More

Comparing the outcomes between prostate surgery and different types of radiotherapy in older patients with prostate cancer.

Comparing the outcomes between prostate surgery and different types of radiotherapy in older patients with prostate cancer.

Posted by on Sep 27, 2021 in Prostate cancer | 0 comments

In a nutshell This study compared the outcomes between radical prostatectomy (RP; prostate-removal surgery) and different types of radiotherapy (RT) in older patients with localized prostate cancer (PCa). The study found that RT offers similar cancer-specific outcomes to RP for low- to intermediate-risk patients. Some background...

Read More

Can robot-assisted prostate surgery improve lower urinary tract symptoms and quality of life in patients with prostate cancer?

Can robot-assisted prostate surgery improve lower urinary tract symptoms and quality of life in patients with prostate cancer?

Posted by on Sep 19, 2021 in Prostate cancer | 0 comments

In a nutshell This study assessed whether robot-assisted radical prostatectomy (RARP) improves lower urinary tract symptoms (LUTS) and quality of life (QoL) in patients with prostate cancer (PCa). The data showed an improvement in LUTS and QoL in patients with previously moderate or severe LUTS, 12 months after RARP. Some background PCa...

Read More

Evaluating the effectiveness and safety of talazoparib for the treatment of patients with metastatic castration-resistant prostate cancer.

Evaluating the effectiveness and safety of talazoparib for the treatment of patients with metastatic castration-resistant prostate cancer.

Posted by on Sep 5, 2021 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety outcomes of talazoparib (Talzenna) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) with mutations in DNA repair genes. The data showed that talazoparib was effective with manageable side effects for these patients. Some background mCRPC is an...

Read More

Evaluating the effects of various treatments on cognitive function in older men with resistant prostate cancer

Evaluating the effects of various treatments on cognitive function in older men with resistant prostate cancer

Posted by on Aug 29, 2021 in Prostate cancer | 0 comments

In a nutshell This study aimed to investigate the link between various treatments for castration-resistant prostate cancer (CRPC) and cognitive (mental) dysfunction in older men. The main finding was that the treatments assessed did not appear to have an impact on cognitive function. Some background CRPC is prostate cancer that keeps growing...

Read More

Evaluating the effectiveness and safety of ipatasertib plus abiraterone and prednisolone for the treatment of patients with metastatic castration-resistant prostate cancer.

Evaluating the effectiveness and safety of ipatasertib plus abiraterone and prednisolone for the treatment of patients with metastatic castration-resistant prostate cancer.

Posted by on Aug 29, 2021 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety outcomes of ipatasertib (GDC-0068) in combination with abiraterone acetate (Zytiga) plus prednisone (Deltasone) (AAP) for the treatment of patients with previously untreated metastatic castration-resistant prostate cancer (mCRPC). The data showed that ipatasertib plus...

Read More

Comparing the outcomes of transvesical or posterior robot-assisted radical prostatectomy for localized prostate cancer.

Comparing the outcomes of transvesical or posterior robot-assisted radical prostatectomy for localized prostate cancer.

Posted by on Aug 22, 2021 in Prostate cancer | 0 comments

In a nutshell This study compared 2 approaches of robot-assisted radical prostatectomy (RARP) for the treatment of localized prostate cancer (PCa). The authors concluded that both transvesical (T) and posterior (P) approaches had similar results in these patients. Some background Localized prostate cancer (PCa) is cancer that is...

Read More

Should 18F-fluciclovine-PET/CT be included into the decision-making process for radiotherapy after surgery for prostate cancer?

Should 18F-fluciclovine-PET/CT be included into the decision-making process for radiotherapy after surgery for prostate cancer?

Posted by on Aug 22, 2021 in Prostate cancer | 0 comments

In a nutshell This study evaluated the role of 18F-fluciclovine-PET-CT versus conventional imaging (bone scan and either CT or MRI) alone for salvage radiotherapy (RT) after prostate surgery for the treatment of patients with localized prostate cancer (PCa). The data showed that including 18F-fluciclovine-PET-CT into the decision-making process for RT...

Read More

Treating castration-resistant prostate cancer that has not spread using new hormonal therapies

Treating castration-resistant prostate cancer that has not spread using new hormonal therapies

Posted by on Aug 15, 2021 in Prostate cancer | 0 comments

In a nutshell This study analyzed the effectiveness and safety of new hormonal therapies (nHTs) in patients with non-metastatic castration-resistant prostate cancer (CRPC). The authors concluded that nHT improved the outcomes of these patients.  Some background CRPC is an aggressive type of prostate cancer that is resistant to androgen...

Read More